01 Growing Prevalence of Cancer and Infectious Diseases The need for diverse biological treatments is rising as the burden of cancer increases. Biopharma companies, both big and small, are still looking for the molecular causes of cancer and making drugs to stop cancer cells from growing. Thus, the biopharma industry is leading in shaping many aspects of the oncology marketplace. In addition, developed and emerging countries face a high burden of infectious diseases. Especially in low- and middle-income nations, contagious diseases, including HIV/AIDS, TB, malaria, and many others, cause a high mortality rate.Infectious diseases are prevalent in developing territories due to the lack of awareness of personal hygiene, low healthcare expenditures, and lack of efficient physician services. The rising incidence of infectious diseases across emerging nations facilitates excellent opportunities for biopharmaceuticals. Drugs have a crucial role in the management of various conditions. Excipients used in manufacturing these biopharma drugs are crucial, and their demand is increasing due to the need for these drugs.
02 Rising Number of Product Approvals for Biologics The biologics industry is increasing, and 40% of estimated biopharmaceuticals are investing in biologics development. The fastest-growing category of therapeutic items is biological products, particularly in the US. Furthermore, there is a growing need for head-to-head studies that compare the safety and effectiveness of different biologics treatment plans. Thus, the development and introduction of new biological drug substances are rising. For instance, the US Food and Drug Administration has approved more than 475 new prescription medications since 2000, including NMEs and new biologic license applications (FDA). These have contributed to new treatment options, resulting in improved length and quality of life, thereby driving market growth.
01 Regulatory Challenges in Manufacturing Biopharmaceutical Excipients One of the main concerns of regulators is the quality and safety of pharmaceutical medicinal goods. By passing stricter restrictions in recent years, regulatory organizations have tightened their stance on preventing the adulteration of pharmaceuticals in excipients and APIs. However, the current regulatory landscape needs an independent excipient approval pathway, which can limit the entry of newer excipients into the market and new drug products. In addition, excipient manufacturers and product developers are hesitant to invest substantial resources and time in developing a new excipient, as it is uncertain that the product will be accepted in the regulatory review, hampering the market growth.
01 Emerging Demand for Novel Excipients in Drug Product Development Novel excipients are a vital part of making sure that new, better, and safe drugs for the biopharmaceutical market are made. Most approved products only contain conventional, well-studied compendial excipients; hence, using novel excipients is unavoidable for formulating some advanced products. In addition, more companies prefer to bring sophisticated and innovative formulations that involve novel excipients. The FDA has defined a novel excipient as one that has not been used in an FDA-approved drug product. Thus, it does not have an established use in food.Additionally, in order to modernize drug formulation and biopharmaceutical development processes, the FDA launches a testing program to check the safety and suitability of novel inactive ingredients in new drugs and biologics applications. The aim is to encourage sponsors of clinical trials to formulate innovative therapies with those new excipients that the FDA finds acceptable for use under this program. An independent approval program will encourage biopharmaceutical companies to evaluate novel excipients and give excipient suppliers a path to market, which does not involve waiting for 15–20 years. This is expected to create tremendous opportunities for market growth over the forecast period.
April 2026 Roquette expanded its pharmaceutical excipient portfolio with the launch of LYCAGEL® Flex, a plant-based hydroxypropyl pea starch designed for softgel capsule formulations. The product broadens formulation options for biopharmaceutical manufacturers seeking animal-free excipients while supporting improved capsule performance and stability.
February 2026 Akums Drugs & Pharmaceuticals received a UK Medicines and Healthcare products Regulatory Agency (MHRA) approval for its manufacturing facility, strengthening its capabilities to supply pharmaceutical products to regulated international markets. The approval enhances the company's position as a manufacturer utilizing advanced pharmaceutical excipients and formulation technologies.
July 2025 Ichnos Glenmark Innovation (IGI), a wholly owned subsidiary of Glenmark Pharmaceuticals, entered into a global licensing agreement with AbbVie for the development and commercialization of the trispecific antibody ISB 2001. The collaboration supports the advancement of biologics requiring specialized excipient formulations for stability and delivery, reinforcing innovation across the biopharmaceutical value chain.